Pivotal trials and novel combinations have started, but four programmes seem to have been discontinued.
ApexOnco Front Page
Recent articles
Varseta-M efficacy wanes, but more than justifies a pivotal trial.
Imlunestrant monotherapy only works in ESR1 mutants, but a Verzenio combo is better in all-comers.
Much has been made of anito-cel’s rivalry with Carvykti, but Arcellx reckons there’s plenty of market for both.
AZD0486 seems highly active, including in patients relapsed on Car-T therapy.
Crossover scuppers Jaypirca's survival benefit, but full approval seems likely.
Inobrodib's first substantial multiple myeloma dataset suggests late-line promise.
But with Brukinsa and degraders looming, will fixed dosing make the difference?
